Metal Chelation Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Overview
Mermaid diagram (expand to render)
Metal chelation therapy aims to restore metal homeostasis in the brain by removing excess transition metals that contribute to oxidative stress, protein aggregation, and neuronal death. Iron and copper accumulation is a hallmark of many neurodegenerative diseases, making metal homeostasis a compelling therapeutic target [@ward2014]. [@zecca2004]
Pathogenic Role of Metal Dysregulation
Iron in Neurodegeneration
Iron accumulation occurs with aging and is accelerated in: [@crapper1991]
Alzheimer's Disease: Iron co-localizes with amyloid plaques and neurofibrillary tangles
Parkinson's Disease: Iron elevation in substantia nigra correlates with dopaminergic neuron loss
ALS: Iron accumulation in motor [cortex](/brain-regions/cortex) and spinal cord
Huntington's Disease: Elevated iron in striatum and cortex [@zecca2004]
Copper Dysregulation
Reduced copper in [neurons](/entities/neurons) despite elevated extracellular copper
Copper deficiency impairs cytochrome c oxidase (Complex IV)
Copper can catalyze toxic [reactive oxygen species](/entities/reactive-oxygen-species) formation
Zinc Homeostasis
Zinc dysregulation affects synaptic function
Zinc can promote [Aβ](/proteins/amyloid-beta) aggregation
Altered zinc transporters in AD and PD
Chelating Agents
Deferoxamine (Desferal)
Evidence in Neurodegeneration:
Reduced MRI iron signals in PD patients
Slowed cognitive decline in AD (limited trials)
Preclinical studies show neuroprotection [@crapper1991]
Deferasirox (Jadenu, Exjade)
Clinical Trials:
Phase 2 trial in PD (completed)
Phase 2 trial in AD (recruiting)
Better tolerability than deferoxamine [@devos2014]
Clioquinol (PBT1)
Clinical Trials:
Phase 2 in AD showed reduced cognitive decline
Discontinued due to formulation issues
Led to second-generation compounds [@ritchie2003]
PBT2
Clinical Trials:
Phase 2A in AD: Reduced [Aβ42](/proteins/amyloid-beta) in CSF
[ClinicalTrials.gov - Iron Chelation Neurodegeneration](https://clinicaltrials.gov/search?cond=neurodegenerative&intr=chelation)
[National Institute of Neurological Disorders](https://www.ninds.nih.gov/)
Background
The study of Metal Chelation Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Ward RJ, Zucca FA, Bellei P, et al, Brain iron metabolism: from molecular mechanisms to clinical significance (2014)](https://doi.org/10.1089/ars.2013.2329)
Crapper McLachlan DR, Dalton AJ, Kruck TP, et al, Intramuscular desferrioxamine in patients with Alzheimer's disease (1991)
Devos D, Moreau C, Devedjian JC, et al, Targeting chelatable iron as a disease-modifying therapy in Parkinson's disease: the FAIRPARKII study (2014)
Ritchie CW, Bush AI, Mackinnon A, et al, Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Aβ amyloid deposition and toxicity in Alzheimer disease: a pilot Phase 2 clinical trial (2003)
Lannfelt L, Blennow K, Zetterberg H, et al, Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a Phase IIa, double-blind, randomised, placebo-controlled trial (2008)
Ayton S, Lei P, Bush AI, Biometals and their therapeutic implications in Alzheimer's disease (2015)
Martin-Bastida A, Lao-Kaim NP, Loane C, et al, Relationship between nigral iron and disease progression in Parkinson's disease: An MRI study (2020)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate